News Brief: Weight Loss Drug Price Deals
Summary
President Donald Trump has secured landmark agreements with pharmaceutical companies Eli Lilly and Novo Nordisk to significantly reduce the out-of-pocket costs for their popular weight loss drugs (GLP-1s). The deals aim to expand access by lowering prices for Medicare, a new direct-to-consumer platform (TrumpRx), and Medicaid.
Key Points
- Deal Overview: Deals with Eli Lilly and Novo Nordisk will slash prices of blockbuster weight loss drugs.
- New Cost Range: Monthly out-of-pocket costs could range from $50 to $350, a significant drop from current list prices above $1,000.
- Medicare Coverage: Medicare will cover GLP-1s for obesity for the first time starting mid-2026. Eligible patients (based on BMI and specific health conditions) may pay a $50 monthly copay.
- Government Price: A new benchmark price of $245 per month for most doses of these drugs for government programs.
- Direct-to-Consumer (TrumpRx): A new platform launching next year will offer injectable GLP-1s starting at $350/month, dropping to $250. Pending obesity pills will start at $149/month.
- Company Platforms: Eli Lilly is also reducing prices on its own direct-to-consumer platform, LillyDirect.
- Medicaid: Lower government pricing is being extended to state Medicaid programs, though states must opt-in.
新闻简报：减肥药价格协议
总结
美国总统唐纳德·特朗普与制药公司礼来和诺和诺德达成了具有里程碑意义的协议，将大幅降低其热门减肥药（GLP-1类药物）的自付费用。这些交易旨在通过降低Medicare（联邦医疗保险）、一个新的直接面向消费者的平台（TrumpRx）以及Medicaid（医疗补助计划）的价格来扩大药物可及性。
关键点
- 协议概述： 与礼来和诺和诺德的协议将大幅降低畅销减肥药的价格。
- 新成本范围： 每月自付费用可能在50美元至350美元之间，较目前超过1000美元的标价大幅下降。
- Medicare覆盖： Medicare将从2026年中期开始首次覆盖用于治疗肥胖症的GLP-1药物。符合条件的患者（基于BMI和特定健康状况）每月可能只需支付50美元共付额。
- 政府价格： 为政府项目设定了这些药物大多数剂量的新基准价格，为每月245美元。
- 直接面向消费者（TrumpRx）： 将于明年推出的新平台将以每月350美元起的价格提供注射型GLP-1药物，未来将降至250美元。待批准的减肥药片起始价格为每月149美元。
- 公司平台： 礼来公司也将在其直接面向消费者的平台LillyDirect上降价。
- Medicaid： 较低的政府定价将扩展到各州的Medicaid计划，但各州必须选择加入。
Original Article Link: https://www.cnbc.com/2025/11/06/obesity-drug-prices-trump-deals-eli-lilly-novo-nordisk.html